•  
  •  
  •  
  •  

2026-02-10 05:37:43

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • UVS Hospitality and Services Ltd announces strategic fundraise and acquisition of Calcio Restaurants in major Expansion Move
  • Cholamandalam Financial Holdings Ltd 9M FY26 consolidated PAT at Rs. 3860 crores
  • Strategic Boost to Atmanirbharta in Shipbuilding as GRSE and HSL Sign MoU
  • India needs nearly 2,000 Exploration Licenses in oil and gas to become energy secured says, Vedanta Group Chairman
  • Nifty steadies after gap-up, recovery attempts gain traction

Keywords Selected:  Pharmaceuticals

Research

  • CRISIL: Pharmaceutical sector set for 8-10% revenue growth this fiscal
  • Kotak Institutional Equities - Pharmaceuticals: IPM pulse - gaining momentum
  • Company Update - P&G Health - ICICI Direct
  • Quant Pick - Cadila Healthcare - ICICI Direct
  • Q2FY22 Result Update - Syngene International - ICICI Direct
  • Syngene International Ltd - Lack of near term triggers - YES Securities
  • Syngene International Ltd - Lower gross margin lead to EBIDTA miss - YES Securities

IPO News

  • Accretion Pharmaceuticals' IPO Opens for subscription today, Price Band set at ₹96-101 per Share
  • Accretion Pharmaceuticals Ltd IPO to open for subscription on May 14, 2025
  • Senores Pharmaceuticals IPO subscribed 13.93 times on Day 2
  • Senores Pharmaceuticals IPO fully subscribed on Day 1
  • Senores Pharmaceuticals gets Sebi nod for IPO

Stock Report

  • Zydus Lifesciences Q3 & 9M FY26: Revenue +30% YoY to ₹686 Cr (Q3), EBITDA +31% at 27%; Net Debt/EBITDA 0.36x
  • Wanbury Limited Q3 FY26: PAT Explodes 1,194% YoY to ₹15.8 Cr, Revenue Up 22%
  • Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets
  • Zydus receives USFDA Orphan Drug Designation (ODD) for Desidustat for the treatment of Sickle Cell Disease
  • Zydus receives tentative approval from USFDA for Dapagliflozin Tablets, 5 mg and 10 mg
  • NATCO receives Tentative Approval for Erdafitinib Tablets from USFDA
  • SPARC announces receipt of Priority Review Voucher associated with Sezaby® Approval
  • Hester receives manufacturing license for Inactivated Avian Influenza Vaccine for poultry
  • Asston Pharmaceuticals Ltd commences commercial production at Unit 2
  • CORONA Remedies Ltd secures Prestigious EAEU-GMP Certification, Strengthening Global Presence
  • Jagsonpal Pharmaceuticals Ltd Q3FY26 profit at Rs. 10.95 crores
  • Lupin and Galenicum Sign License and Supply Agreement for Semaglutide in 23 Countries
  • Senores Pharmaceuticals Ltd consolidated Q3FY26 profit at Rs. 33.58 crores
  • Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035
  • JB Chemicals & Pharmaceuticals Ltd records revenue growth of 11% to INR 1065 crores in Q3 FY26
  • Medicamen Biotech Ltd gets EU approval for Paracetamol from Danish Medicine Authority
  • Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
  • Wockhardt files Marketing Authorisation Application for WCK 5222 with European Medicines Agency
  • Shukra Pharmaceuticals Ltd inks MOU with Borns Medical Robotics Inc., USA
  • Syschem India Ltd commences Commercial Production at New Ganga Unit and Saru Expansion, Boosting Capacity by 1,800 MT
  • Caplin acquires 10 approves ANDAs injection and Opthalmic products
  • European Medicines Agency Grants Accelerated Assessment to WCK 5222
  • Concord Drugs Ltd receives orders worth Rs. 14.71 crores
  • Lupin signs exclusive licensing agreement with Gan & Lee Pharmaceuticals for novel GLP-1 receptor agonist

Industry News

  • NYSE Listed Amneal Pharmaceuticals begins Commercial Operations in India

Latest Post

  • UVS Hospitality and Services Ltd announces strategic fundraise and acquisition of Calcio Restaurants in major Expansion Move
  • Cholamandalam Financial Holdings Ltd 9M FY26 consolidated PAT at Rs. 3860 crores
  • Strategic Boost to Atmanirbharta in Shipbuilding as GRSE and HSL Sign MoU
  • India needs nearly 2,000 Exploration Licenses in oil and gas to become energy secured says, Vedanta Group Chairman
  • Nifty steadies after gap-up, recovery attempts gain traction


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025